Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $566.00 at The Goldman Sachs Group

Key Points

• Goldman Sachs has raised the target price for Alnylam Pharmaceuticals from $504.00 to $566.00, indicating a potential upside of 22.87% from its current price.
• The company reported a quarterly earnings surprise, with earnings per share of $0.32, surpassing estimates by $0.86, and a revenue of $773.69 million, exceeding expectations by $140.15 million.
• Multiple analysts have recently upgraded their target prices for Alnylam, with a consensus target price of $426.85 and a majority rating it as a "Moderate Buy".

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its target price raised by investment analysts at The Goldman Sachs Group from $504.00 to $566.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's target price suggests a potential upside of 22.87% from the company's current price.

ALNY has been the topic of a number of other reports. UBS Group raised their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Needham & Company LLC raised their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday, August 1st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $426.85.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded down $0.50 on Tuesday, hitting $460.65. The stock had a trading volume of 187,217 shares, compared to its average volume of 969,982. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market cap of $60.38 billion, a price-to-earnings ratio of -186.47 and a beta of 0.32. The company's 50-day moving average is $404.20 and its two-hundred day moving average is $319.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. During the same period last year, the firm posted ($0.13) earnings per share. The business's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the sale, the director owned 775 shares in the company, valued at $362,390. The trade was a 95.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares of the company's stock, valued at $7,561,800. This represents a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 75,594 shares of company stock worth $33,968,256 in the last quarter. Corporate insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $662,837,000. Holocene Advisors LP purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $194,616,000. Orbis Allan Gray Ltd raised its holdings in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $69,292,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.